Burden of Liver Diseases: A Review from Iran

Anushiravani, Amir; Sepanlou, Sadaf G

doi:10.15171/mejdd.2019.147

Cited by 28 publications

(26 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NAFLD has become the most common chronic liver disease in the western world, accounting for about 25% of the total population, and will continue to increase in the future 1 , 5 , 6 , 8 , 28 , 29 . NAFLD can progress through more severe NASH, cirrhosis, and, lastly, HCC 30 – 33 . It is now considered as a multifactorial condition that leads not only to increased liver-related mortality but also to increased risk of the development of type 2 diabetes mellitus and cardiovascular disease 34 .…”

Section: Discussionmentioning

confidence: 99%

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Wang

et al. 2021

Nat Commun

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in the world, however, no drug treatment has been approved for this disease. Thus, it is urgent to find effective therapeutic targets for clinical intervention. In this study, we find that liver-specific knockout of PPDPF (PPDPF-LKO) leads to spontaneous fatty liver formation in a mouse model at 32 weeks of age on chow diets, which is enhanced by HFD. Mechanistic study reveals that PPDPF negatively regulates mTORC1-S6K-SREBP1 signaling. PPDPF interferes with the interaction between Raptor and CUL4B-DDB1, an E3 ligase complex, which prevents ubiquitination and activation of Raptor. Accordingly, liver-specific PPDPF overexpression effectively inhibits HFD-induced mTOR signaling activation and hepatic steatosis in mice. These results suggest that PPDPF is a regulator of mTORC1 signaling in lipid metabolism, and may be a potential therapeutic candidate for NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Wang

et al. 2021

Nat Commun

View full text Add to dashboard Cite

show abstract

“…In this context, worsening diabetes and obesity rates have been shown to be the main driver of this trend in MENA countries. In fact, recent studies from the United Arab Emirates, Iran or Turkey clearly demonstrate a disquieting trend in the rates of obesity, diabetes and NAFLD (25,26). For example, it is estimated that the number of patients with NAFLD will increase by 47% between 2017 and 2030 in the United Arab Emirates, while the projection for NASH increase is 97% in Saudi Arabia and 87% in UAE (27).…”

Section: Global Prevalence Of Nafldmentioning

confidence: 99%

Nonalcoholic steatohepatitis: global impact and clinical consequences

Kabarra

Golabi

Younossi

2021

Endocrine Connections

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver diseases ranging from simple fatty infiltration of liver parenchyma to the potentially progressive type of NAFLD called nonalcoholic steatohepatitis (NASH). Given the obesity epidemic, NAFLD and NASH have reached alarming levels globally. Recent data suggest that more than a quarter of the world population is affected by NAFLD, however, the disease prevalence is higher in certain patient population, i.e. 55% prevalence rate among patients with type 2 diabetes (T2DM). Besides T2DM, NAFLD is also closely related to other metabolic abnormalities, such as visceral obesity, hypertension and hyperlipidemia. It has been suggested that stage of liver fibrosis is the most important factor associated with mortality among NAFLD. Additionally, patients with T2DM have increased risk of adverse outcomes. In addition to these metabolic abnormalities, older age and some genetic factors could pose additional risks. Patients with NAFLD and NASH have significantly impaired health related quality of life than the general population. There is also a growing economic impact of NAFLD and NASH on healthcare systems around the globe. Despite a number of promising regimens as treatment options, healthy lifestyle modification with diet and exercise remain at the core of management of NAFLD and NASH.

show abstract

“…ТМД может быть выполнена через стенку двенадцатиперстной кишки или желудка в зависимости от расположения псевдокисты. Требования к выполнению ТМД включают: расстояние < 1 см между псевдокистой и стенкой кишечника или желудка при визуализации, четкое прилежание стенки кишечника или желудка при эндоскопии, отсутствие варикозного расширения вен, отсутствие псевдоаневризм и исключение злокачественных образований до начала лечения [51,56].…”

Section: эндоскопическое дренированиеunclassified

Current treatment of pancreatic pseudocysts: a systematic review

Durleshter¹,

Генрих

Макаренко³

et al. 2021

Kuban. nauсh. med. vestnik

View full text Add to dashboard Cite

Background. Pancreatic pseudocysts stand among current challenges in modern medicine. Their treatment uses variant instrumental techniques and implies a multispecialty approach. Trials in surgery and gastroenterology have aimed to identify an optimal strategy to tackle pancreatic pseudocysts for reducing complications and the recurrence rate, suggesting ultrasound-guided percutaneous, laparoscopic and flexible endoscopic drainage as promising treatment choices.Objectives. A summarising review of diagnostic and therapeutic methods for pancreatic pseudocyst treatment and comparison of ultrasound-guided percutaneous vs. surgical and endoscopic drainage techniques.Methods. The review examines the classification, epidemiology and methods for diagnosis and treatment of pancreatic pseudocysts. Only comparative full-text studies published within 2014–2021, as well as selected impactive publications within 2002–2013, have been included. The eLibrary, Elsevier and PubMed resources were queried for the article or journal title fields against the keywords (separate or combined) “pancreatic pseudocyst” [псевдокиста поджелудочной железы], “pseudocyst drainage” [дренирование псевдокисты], “surgical drainage” [хирургическое дренирование], “endoscopic drainage” [эндоскопическое дренирование], cystogastrostomy [цистогастростомия], gastrojejunostomy [гастроеюностомия], “duodenal-cystic anastomosis” [цистодуоденоанастомоз], “transpapillary drainage” [транспапиллярное дренирование], “transmural drainage and esophagogastroduodenoscopy” [трансмуральное дренирование и эзофагогастродуоденоскопия]. Records have been selected for topic-related scientific value.Results. The review systematically surveys 68 scientific papers in the focus area and summarises the most common surgical methods for pancreatic pseudocyst treatment. Based on the main principle, the methods are classified into three categories, ultrasound-guided percutaneous drainage, surgical drainage and flexible endoscopic drainage. The major classifications and treatment techniques are highlighted for their advantages and disadvantages.Conclusion. There exist no generally adopted strategy for pancreatic pseudocyst treatment in current clinical practice and no evidence on a particular method application in a large patient cohort. The publication survey identifies the techniques of percutaneous, surgical and endoscopic drainage with ultrasound control as highly effective overall among other surgical treatments.

show abstract

Burden of Liver Diseases: A Review from Iran

Cited by 28 publications

References 17 publications

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Nonalcoholic steatohepatitis: global impact and clinical consequences

Current treatment of pancreatic pseudocysts: a systematic review

Contact Info

Product

Resources

About